<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01443650</url>
  </required_header>
  <id_info>
    <org_study_id>PKD12275</org_study_id>
    <secondary_id>U1111-1120-0670</secondary_id>
    <nct_id>NCT01443650</nct_id>
  </id_info>
  <brief_title>Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects</brief_title>
  <official_title>A Randomized Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics After Different Single-Dose Subcutaneous Treatments of SAR236553/REGN727 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      Injection Site Tolerability

      Secondary Objectives:

        -  To assess the safety profile of alirocumab SAR236553 (REGN727)

        -  To assess the pharmacokinetic-pharmacodynamic relationship of alirocumab SAR236553
           (REGN727)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total duration for each subject (not including screening) will be approximately 85 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain using Present Pain Intensity (PPI) verbal questionnaire and Visual Analog Scale (VAS)</measure>
    <time_frame>15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Erythema at injection site by measuring diameter and qualitative assessment</measure>
    <time_frame>15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Edema at injection site by measuring diameter and qualitative assessment</measure>
    <time_frame>15 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter - time to maximum concentration (tmax)</measure>
    <time_frame>Up to 85 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Change in LDL-C from baseline</measure>
    <time_frame>Up to 85 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>Up to 85 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter - maximum concentration (Cmax)</measure>
    <time_frame>Up to 85 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter - area under curve (AUC)</measure>
    <time_frame>Up to 85 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter - area under curve versus time curve (AUC0-D29)</measure>
    <time_frame>Zero to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter - plasma concentration on Day 29 (C D29)</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter - terminal elimination half-life (t1/2z)</measure>
    <time_frame>Up to 85 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>alirocumab SAR236553 (REGN727) (Formulation A x 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of Formulation A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>alirocumab SAR236553 (REGN727) (Formulation B x 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of Formulation B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>alirocumab SAR236553 (REGN727) (Formulation A x 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 single subcutaneous injections of Formulation A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alirocumab SAR236553 (REGN727)</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: subcutaneous</description>
    <arm_group_label>alirocumab SAR236553 (REGN727) (Formulation A x 1)</arm_group_label>
    <arm_group_label>alirocumab SAR236553 (REGN727) (Formulation B x 1)</arm_group_label>
    <arm_group_label>alirocumab SAR236553 (REGN727) (Formulation A x 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Serum LDL-C levels &gt;100 mg/dL.

        Exclusion criteria:

          -  Subjects indicated for the use of statins according to criteria in Adult Treatment
             Program (ATP) III Guidelines, as updated in 2004.

          -  Initiation of a new diet or major change to a previous diet within 4 weeks prior to
             Screening. Subjects must be willing to maintain a consistent diet for the duration of
             the study.

          -  Use of a medication or nutraceutical in order to alter serum lipids within 4 weeks
             prior to screening, including but not limited to statins, cholesterol absorption
             inhibitors, fibrates, niacin, bile acid resins, or red yeast rice.

          -  Fasting serum triglycerides &gt;200 mg/dL measured after an 8-12 hour fast.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2011</study_first_submitted>
  <study_first_submitted_qc>September 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2011</study_first_posted>
  <last_update_submitted>June 27, 2013</last_update_submitted>
  <last_update_submitted_qc>June 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

